Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
36,566
Total Claims
$5.2M
Drug Cost
725
Beneficiaries
$7,232
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+577%
Cost per patient vs peers
$7,232 vs $1,068 avg
+135%
Brand preference vs peers
21.1% vs 9.0% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
🔎 Data Overview
Cost per patient is 577% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 7,593 claims · $4.2M
Generic: 28,367 claims · $992K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Diclofenac Epolamine | 1,194 | $868K |
| Icosapent Ethyl | 1,874 | $804K |
| Tenofovir Alafenamide | 214 | $328K |
| Sitagliptin Phosphate | 329 | $242K |
| Lipase/Protease/Amylase | 230 | $218K |
| Dapagliflozin Propanediol | 228 | $152K |
| Sitagliptin Phos/Metformin Hcl | 216 | $145K |
| Cyclosporine | 152 | $126K |
| Empagliflozin | 162 | $119K |
| Diclofenac Sodium | 392 | $106K |
| Denosumab | 60 | $103K |
| Apixaban | 148 | $101K |
| Rivaroxaban | 147 | $93K |
| Linaclotide | 106 | $70K |
| Linagliptin | 92 | $61K |
Prescribing Profile
Patient Profile
73
Avg Age
55%
Female
1.29
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data